Acute Sensorineural Hearing Loss - Pipeline Review, H2 2014 market analysis

1
Acute Sensorineural Hearing Loss - Pipeline
Review, H2 2014
No. Pages 47
Published on Dec-2014
2
Report Description
Global Markets Directs, Acute Sensorineural
Hearing Loss - Pipeline Review, H2 2014,
provides an overview of the Acute Sensorineural
Hearing Losss therapeutic pipeline. This report
provides comprehensive information on the
therapeutic development for Acute Sensorineural
Hearing Loss, complete with comparative analysis
at various stages, therapeutics assessment by
drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type, along
with latest updates, and featured news and press
releases. It also reviews key players involved in
the therapeutic development for Acute
Sensorineural Hearing Loss and special features
on late-stage and discontinued projects. To Get
More Info. Visit http//www.analyzefuture.com/a
cute-sensorineural-hearing-loss-pipeline-review-h2
-2014-market Global Markets Directs report
features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and
information sourced from Global Markets Directs
proprietary databases, Company/University
websites, SEC filings, investor presentations and
featured press releases from company/university
sites and industry-specific third party sources,
put together by Global Markets Directs team.
3
Report Description
Drug profiles/records featured in the report
undergoes periodic updation following a stringent
set of processes that ensures that all the
profiles are updated with the latest set of
information. Additionally, processes including
live news deals tracking, browser based
alert-box and clinical trials registries tracking
ensure that the most recent developments are
captured on a real time basis. The report
enhances decision making capabilities and help to
create effective counter strategies to gain
competitive advantage. It strengthens RD
pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class
products. To Enquire About Report _at_
http//www.analyzefuture.com/acute-sensorineural-h
earing-loss-pipeline-review-h2-2014-market/report-
enquiry
4
Table of Content
Table Of ContentsTable of ContentsTable of
Contents 2List of Tables 4List of Figures
4Introduction 5Global Markets Direct Report
Coverage 5Acute Sensorineural Hearing Loss
Overview 6Therapeutics Development 7Pipeline
Products for Acute Sensorineural Hearing Loss -
Overview 7Pipeline Products for Acute
Sensorineural Hearing Loss - Comparative Analysis
8Acute Sensorineural Hearing Loss - Therapeutics
under Development by Companies 9Acute
Sensorineural Hearing Loss - Pipeline Products
Glance 10Late Stage Products 10Clinical Stage
Products 11Early Stage Products 12Acute
Sensorineural Hearing Loss - Products under
Development by Companies 13Acute Sensorineural
Hearing Loss - Companies Involved in Therapeutics
Development 14
5
Table of Content
Nordmark Arzneimittel GmbH Co. KG 14Orbis
Biosciences, Inc. 15Otologic Pharmaceutics, Inc.
16Pfizer Inc. 17Sound Pharmaceuticals, Inc.
18Xigen SA 19Acute Sensorineural Hearing Loss -
Therapeutics Assessment 20Assessment by
Monotherapy Products 20Assessment by Combination
Products 21Assessment by Target 22Assessment by
Mechanism of Action 24Assessment by Route of
Administration 26Assessment by Molecule Type
28Drug Profiles 30(acetylcysteine disufenton
sodium) - Drug Profile 30Product Description
30Mechanism of Action 30RD Progress 30ancrod
- Drug Profile 31
6
Table of Content
Product Description 31Mechanism of Action 31RD
Progress 31betamethasone valerate - Drug Profile
33Product Description 33Mechanism of Action
33RD Progress 33PF-04958242 - Drug Profile
34Product Description 34Mechanism of Action
34RD Progress 34Small Molecules to Inhibit
Gamma Secretase for Sensorineural Hearing Loss -
Drug Profile 35Product Description 35Mechanism
of Action 35RD Progress 35SPI-1005 - Drug
Profile 36Product Description 36Mechanism of
Action 36RD Progress 36
7
Table of Content
Stem Cell Therapy for Sensorineural Hearing Loss
- Drug Profile 38Product Description
38Mechanism of Action 38RD Progress 38XG-102
- Drug Profile 39Product Description
39Mechanism of Action 39RD Progress 39Acute
Sensorineural Hearing Loss - Recent Pipeline
Updates 41Acute Sensorineural Hearing Loss -
Product Development Milestones 43Featured News
Press Releases 43Nov 19, 2014 Otologic
Pharmaceutics Initiates Phase 1 Clinical Study of
NHPN-1010 for Hearing Disorders 43Feb 18, 2014
Sound Pharmaceuticals submits positive Phase 2
clinical trial data on SPI-1005 for the
prevention and treatment of sensorineural hearing
loss 43Dec 05, 2012 University Of Florida
Begins Phase-II Trial With Sound Pharma's
SPI-1005 To Prevent Hearing Loss 44 To Get
Complete TOC Visit at http//www.analyzefutu
re.com/acute-sensorineural-hearing-loss-pipeline-r
eview-h2-2014-market/table-of-contents
8
FOR MORE DETAILS
Visit us at
http//www.analyzefuture.com/
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States.
TELEPHONE [phone] EMAIL
sales_at_analyzefuture.com